



Correction to: Statins, metformin, proprotein-convertase-subtilisin-kexin type-9 (PCSK9) inhibitors and sex hormones: Immunomodulatory properties?

Christian A. Koch^{1,2,3,4,5} · Siegfried Krabbe^{1,2,6} · Bernd Hehmke⁷

Published online: 23 March 2019

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Correction to: Reviews in Endocrine and Metabolic Disorders (2018) 19:363–395

<https://doi.org/10.1007/s11154-018-9478-8>

The authors would like to note that several errors had occurred, especially in Table 2, Tables 5, 6 and 7, Figure 13, and in the legend of Figure 23.

On page 365, right column, bottom, and on page 366, left column, top, the sentence should read “...role in the pathogenesis of autoimmune thyroid disease, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, and others.”

On page 368, Table 2, left column, under the heading “Criterion” the following typographical errors should be corrected to the vertical column:

Increased frequency.....

Increased responsiveness of IL-10...

Enhancements of upregulated...

The online version of the original article can be found at <https://doi.org/10.1007/s11154-018-9478-8>

✉ Christian A. Koch
Christian.koch65@gmail.com

✉ Bernd Hehmke
ehmke@diabetes-karlsburg.de

Siegfried Krabbe
Dr.siegfried_krabbe@gmx.de

¹ Medcover GmbH Berlin, Berlin, Germany

² Carl von Ossietzky University, Oldenburg, Germany

³ Technical University of Dresden, Dresden, Germany

⁴ University of Louisville, Louisville, KY, USA

⁵ University of Tennessee Health Science Center, Memphis, TN, USA

⁶ University of Greifswald, Greifswald, Germany

⁷ Institute of Diabetes “Gerhardt Katsch”, Karlsburg, Germany

Table 7 Effect of the lipid-lowering drug simvastatin on the frequency of proinflammatory Interferon-gamma+ and regulatory IL-10+ thyroid-autoreactive CD4+ T helper cells in patients with autoimmune thyroiditis in comparison to untreated patients and healthy donors

Group	Cytokine phenotype of thyroid-autoreactive T cells [§] (frequency)						
	Tr1	Tr0	Th1	Tr1+Tr0	Tr0+Th1	Tr1+Th1	Tr1+Tr0+Th1
Thyreoiditis, without simvastatin treatment (<i>n</i> =31)	4.83 %	7.25 %	6.34 %*	10.57 %	2.11 %	0.30 %	2.11 %
Thyreoiditis, treated with 40 mg/d simvastatin (<i>n</i> =7)	10.39 %	10.39 %	1.30 %	19.48 %* [‡]	0.00 %	0.00 %	0.00%
Healthy donors (<i>n</i> =29)	8.57 %	10.15 %	0.00 %	8.89%	2.54 %	0.32 %	0.63 %

Data are given as percentage of T cell cultures with the corresponding cytokine phenotype in relation to the total number of T cell test cultures

[§] Tr1: T regulatory type 1, IL-10+; Tr0: T regulatory type 0, IFN-γ+IL-10+; Th1: T helper type 1, IFN-γ+

**p* < 0.0001 vs. healthy donors; [‡]*p* = 0.032 vs. thyroiditis without simvastatin; #*p* = 0.008 vs. healthy donors; χ²-test

Graves' Orbitopathy – Immunomodulatory Therapy




Fig. 13 Statins as immunomodulatory therapy in GO

On page 371, in Figure 13 the blue cell “Th” should be corrected to “Th1”.

On page 375, right column, middle section, the sentence should read “...in Table 8 revealed a statin-induced....”

On page 386, the legend of Figure 23 at the end of the page should be corrected to “...whereas few unbalanced IL-17+ IFN-gamma+ Th17/Th1 cells responding to peptide 9 were found....”

On page 375 in Table 5 and on page 388 in Table 6 “Mal. weight” should be corrected to “Mol. weight”.

On page 389, in Table 7 the horizontal line under “Group” should be corrected as well as the table legend, see reprinted Table 7.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.